{"id":"NCT03078075","sponsor":"University of Texas Southwestern Medical Center","briefTitle":"Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder","officialTitle":"NIDA (National Institute on Drug Abuse) CTN (Clinical Trials Network) Protocol 0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-05","primaryCompletion":"2019-07-03","completion":"2019-07-25","firstPosted":"2017-03-13","resultsPosted":"2021-03-29","lastUpdate":"2021-05-03"},"enrollment":403,"design":{"allocation":"RANDOMIZED","model":"SEQUENTIAL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Methamphetamine Use Disorder"],"interventions":[{"type":"DRUG","name":"Naltrexone: Vivitrol®","otherNames":["Arm: Experimental - Active Medication Combination (AMC)"]},{"type":"DRUG","name":"Placebo (PLB) Injectable","otherNames":["Injectable matching (to Naltrexone) placebo","Arm: Placebo Comparator - matched Placebo (PLB)"]},{"type":"DRUG","name":"Bupropion: Wellbutrin XL®","otherNames":["Arm: Experimental - Active Medication Combination (AMC)"]},{"type":"DRUG","name":"Placebo (PLB) Oral","otherNames":["Oral matching (to Bupropion) placebo tablets","Arm: Placebo Comparator - matched Placebo (PLB)"]}],"arms":[{"label":"Active Medication Combination (AMC)","type":"EXPERIMENTAL"},{"label":"Matched Placebo (PLB)","type":"PLACEBO_COMPARATOR"}],"summary":"This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Participants will be randomly assigned to the active medication combination (AMC) group or matching placebo group and will receive medications over the course of 12 weeks. Follow-ups will occur in weeks 13 and 16.","primaryOutcome":{"measure":"Number of Participants With Treatment Response During Medication Phase at Stage 1","timeFrame":"At weeks 6","effectByArm":[{"arm":"Stage 1 Placebo","deltaMin":10,"sd":null},{"arm":"Stage 1 AMC","deltaMin":18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":6},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":["40767786","38665252","37377462","37245855","33497547"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":294},"commonTop":["Nausea"]}}